TriangleAd-hCMV-Flt3L (NCT06914479)
Ad-hCMV-Flt3L trial for Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant (NCT06914479). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
When a malignant brain tumor returns in a child or young adult, surgery removes what is visible; the cells left behind regrow.
The idea: at surgery, seed the tumor bed with two viruses, one that kills, one that calls the immune system in.
At the University of Michigan, once the tumor is out, the surgeon injects two modified adenoviruses into the surrounding brain. One carries a herpes gene that turns the oral drug valacyclovir into a poison inside dividing tumor cells. The other carries Flt3L, which summons dendritic cells, so the dying tumor is shown to the immune system. Valacyclovir is taken two weeks per cycle.
Early safety study, ages three to thirty-nine. Andrea Franson leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.